We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Safety Review of Heart Risks Surrounding Hypertension Drug Benicar Are Inconclusive
FDA Safety Review of Heart Risks Surrounding Hypertension Drug Benicar Are Inconclusive
After an exhaustive review, the FDA found no clear evidence of higher cardiovascular risks for diabetic patients taking olmesartan, and declined to set new restrictions on use of the widely-prescribed hypertension drug.